Abstract

Over the past decade, psychedelic research has experienced remarkable growth, with several Phase 3 clinical trials currently underway. Despite these advancements, the translation of psychedelic therapies into clinical practice faces significant challenges, requiring rigorous scientific investigation, thorough legal and ethical analysis, and extensive interdisciplinary collaboration. This presentation will provide a comprehensive review of the latest advancements in Psychedelic and Empathogen-Assisted Therapy, highlighting key findings and emerging trends in the field. Special attention will be given to the establishment of the Cambridge Psychedelic Research Group, which, in 2024, received the first-ever Home Office Schedule 1 Licence for the East of England, marking a critical milestone in the integration of psychedelic research within the region. By exploring how psychedelics and empathogens may offer new hope for individuals with treatment-resistant mental health conditions, the presentation will emphasize the importance of continued research and the need for interdisciplinary collaboration in this rapidly evolving field.